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trans-Sialidase is an enzyme present on the surface of Trypanosoma cruzi and is an important antigen
recognized by sera from patients with Chagas’ disease. In the present study we investigated whether the
benznidazole treatment of patients with Chagas’ disease induced changes in the reactivity of serum toward a
recombinant form of trans-sialidase in order to develop an assay for monitoring of patients after treatment for
Chagas’ disease, which is needed at Chagas’ disease control centers. By using an enzyme-linked immunosor-
bent assay containing a recombinant protein corresponding to the catalytic domain of trans-sialidase, we found
that the antigen had a high specificity for sera from untreated patients with Chagas’ disease. Sera from healthy
individuals or patients with active visceral leishmaniasis minimally cross-reacted with the antigen. Anti-trans-
sialidase immunoglobulin was detected in 98% of 151 untreated patients with Chagas’ disease. Of these, 124
patients were treated for 60 days with benznidazole (5 mg/kg of body weight/day), and their sera were assayed
for reactivity with the recombinant trans-sialidase. By using this methodology, three groups of patients could
be established. The first group (60 patients), which was considered to have been successfully treated, showed
no reactivity after treatment. The second group (46 patients) still showed signs of infection, and after treatment
their sera recognized trans-sialidase, but with reduced titers. The third group (18 patients) was considered to
be resistant to drug treatment, and their sera presented identical reactivities before and after treatment. These
results suggest that determination of the absence of antibodies to recombinant trans-sialidase in treated
patients by the present assay is indicative of treatment success, while the presence of antibodies may indicate
the persistence of infection. Therefore, this method may be useful for the diagnosis and monitoring of patients
undergoing benznidazole treatment.
Chagas’ disease is a chronic illness that affects 16 million to
18 million people in Latin America. It is a prevalent infection
in areas where the disease is highly endemic and where the
vectorial transmission of Trypanosoma cruzi has not been elim-
inated or controlled (20, 31). The natural cycles involving tri-
atomine bugs, wild and domestic reservoirs, as well as humans
are still responsible for new cases of the disease; and a large
number of patients still require drug treatment (8).
After the acute phase following T. cruzi infection, parasites
are rarely found in blood, and the diagnosis is mainly based on
serology. Blood centers and clinical laboratories generally use
hemagglutination, immunofluorescence, and enzyme-linked
immunosorbent assay (ELISA) with serum for the diagnosis of
Chagas’ disease by using antigens extracted from epimastig-
otes, the noninfective stage of T. cruzi. However, conventional
serology is unable to distinguish whether patients treated with
benznidazole are cured. A considerable number of results are
inconclusive, even when different serological tests are used (2,
11, 17).
We have developed an ELISA using a recombinant protein
corresponding to the N-terminal portion of the T. cruzi trans-
sialidase (TS). This enzyme is produced by bloodstream trypo-
mastigotes of T. cruzi, the parasite form responsible for dis-
seminating the infection in mammalian hosts. TS contains two
domains. One includes the active site and is located at the N
terminus. The other is composed of 12-amino-acid repeats and
is located at the C terminus (10, 28). The enzyme’s N-terminal
domain is responsible for the induction of specific antibodies
that inhibit the enzymatic activity of TS during infection (14,
23, 24). Moreover, the N-terminal domain has important roles
in the humoral (6, 15, 23) and cellular (26, 27) immune re-
sponses that control infection. Therefore, we aimed to inves-
tigate whether sera from patients with Chagas’ disease specif-
ically recognize this recombinant TS and if this recognition
decreases in patients undergoing anti-T. cruzi chemotherapy
with benznidazole.
MATERIALS AND METHODS
Patients and diagnosis. A total of 124 adult patients with chronic Chagas’
disease from the Laboratory of Xenodiagnosis, Instituto Dante Pazzanese de
Cardiologia, Sa˜o Paulo, Brazil, were evaluated by clinical and serological meth-
ods. Chagas’ disease was diagnosed primarily on the basis of clinical examination,
electrocardiogram, chest X ray, and conventional serological methods, including
an indirect hemagglutination test (Biolab Me´rieux Ltda, Sa˜o Paulo, Brazil) (5),
an indirect immunofluorescence test with formaldehyde-fixed epimastigotes as
antigen (4), and ELISA (Laborato´rios Salk, Sa˜o Paulo, Brazil). None of the
patients included in this study presented with cardiac alterations (indeterminate
form), and before treatment all had sera produceding positive reactions by all
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three tests mentioned above. In addition, the patients were hemoculture positive
(22).
Chemotherapy and evaluation. Patients were treated for 60 days with 5 mg of
benznidazole per kg of body weight per day (9). After treatment, they were
evaluated for several years by clinical examination and parasitological and sero-
logical tests at 1-year intervals. Treatment and clinical evaluation were per-
formed by one of us (Abilio Augusto Fragata-Filho). This protocol for the
treatment of patients with Chagas’ disease is traditionally used at the Instituto
Dante Pazzanese de Cardiologia, Sa˜o Paulo, which focuses mainly on the cardiac
involvement and evolution of Chagas’ disease (9).
Serum samples. The sensitivity and specificity of TS were determined by
assaying 201 serum samples from 151 patients with chronic Chagas’ disease
before the specific treatment, 40 healthy individuals who had never lived in an
area where T. cruzi is endemic and who were negative for Chagas’ disease by
conventional serological methods, and 10 patients with active visceral leishman-
iasis (which was diagnosed serologically by the Laboratory of Parasitology, In-
stituto Aldofo Lutz). The evolution of treatment was analyzed by assaying 372
samples, 124 samples before treatment and 248 samples 1 and 2 years after
treatment. All sera used in this study were stored at20°C without additives and
were colleted from individuals who had given informed consent to participate in
this protocol, which was approved by the Ethics Committees of the Instituto
Dante Pazzanese de Cardiologia and Instituto Adolfo Lutz.
Recombinant TS production and purification. Recombinant TS was generated
and purified from Escherichia coli cells transformed with plasmid pTS-cat7, as
described previously (25). The purity of each TS batch was checked by sodium
dodecyl sulfate–10% polyacrylamide gel electrophoresis (SDS-PAGE) (12), and
the protein concentration was estimated by the Bradford procedure (12).
TS ELISA. The TS ELISA was performed with microtiter polystyrene plates
(flat bottom; Corning) coated with the recombinant TS. Each well was incubated
overnight at 4°C with 200 ng of recombinant TS dissolved in 0.1 ml of 0.1 M
NaHCO3 (pH 8.5). Unbound antigen was removed by washing the plates with
phosphate-buffered saline (PBS; pH 7.2) containing 0.05% Tween 20. The free
binding sites were blocked by treating the wells with 5% skim milk–PBS. After
2 h, 50 l of each serum sample diluted 1:50 in 5% skim milk–PBS was incubated
for 60 min at 37°C. After five washes with PBS-Tween 20, the wells were
incubated for 30 min at 37°C with a horseradish peroxidase-conjugated goat
anti-human immunoglobulin G (IgG; Life Technologies) diluted 1:10,000 in 5%
skim milk–PBS. After a new wash cycle with PBS-Tween 20, substrate solution
(0.1 M citric acid, 0.2 M Na2HPO4, 0.05% o-phenylenediamine, 0.1% H2O2) was
added to each well, and the plates were left to stand at room temperature in the
dark for 15 min. Color development was stopped by adding 50 l of 4 N H2SO4,
and the absorbance was measured with an ELISA reader (Multiscan) with a
492-nm filter. To standardize the ELISA reaction, 20 serum samples from
healthy individuals and 20 serum samples from patients with Chagas’ disease
with different concentrations of T. cruzi antibodies, as determined by conven-
tional serology, were used. Different concentrations of purified recombinant TS
(0.1 to 5 g/ml) on the microtiter plates, different conjugate dilutions (1/100 to
1/100,000), and different serum dilutions (1/5 to 1/500) were tested (data not
shown). The optimal TS concentration was 2 g/ml, and the optimal conjugate
dilution was 1:10,000. Each serum sample was assayed in duplicate. The absor-
bance values were subtracted from the background, and the arithmetic mean was
calculated. The cutoff for each reaction was three times the mean and standard
deviation for 20 serum samples from healthy individuals. The values shown in the
figures represent the absorbance at 492 nm relative to the cutoff absorbances.
Immunoblotting. SDS-PAGE and immunoblotting with purified recombinant
TS were performed as described previously (30). One microgram of TS was
loaded, fractionated by SDS–10% PAGE, and transferred to nitrocellulose mem-
branes. The membranes were cut into 3- to 4-mm-wide strips, blocked for 2 h
with 5% skim milk–PBS, and incubated with serum diluted 1:50 at 37°C. After
1 h, the strips were washed with PBS and incubated for 30 min at 37°C with goat
horseradish peroxidase-conjugated anti-human IgG diluted in 1% skim milk–
PBS. Bound antibodies were visualized after incubation with 0.017% diamino-
benzidine and 0.1% H2O2 in PBS.
RESULTS
Sensitivity and specificity of TS as antigen in ELISA. Spec-
ificity and sensitivity were assessed by testing 40 serum samples
from apparently healthy individuals, 10 serum samples from
patients with active visceral leishmaniasis, and 151 serum sam-
ples from untreated patients with chronic Chagas’ disease. The
absorbance at 492 nm of each serum sample was read and
expressed as the ratio of the absorbance relative to that for the
control sera. The values obtained are shown in Fig. 1; and a
summary of the results, including the specificity and sensitivity
for each group, is presented in Table 1. The mean value for
sera from patients with Chagas’ disease was 1.93. In this group,
three serum samples presented values below 1.0, giving a sen-
sitivity of 0.98 for the assay. In contrast, the serum samples
from healthy individuals presented a mean value of 0.51. Three
serum samples presented values greater than 1.0, resulting in a
FIG. 1. Reactivities of sera from healthy individuals (squares), pa-
tients with Chagas’ disease (circles), and patients with leishmaniasis
(triangles) against recombinant TS by the TS ELISA. The results were
calculated as the ratio of the absorbance of each serum sample at an
optical density of 492 nm (A492) to the cutoff value. Values greater than
1.0 were considered reactive. The horizontal lines represent the arith-
metic means.
TABLE 1. Sensitivity, specificity, and 95% confidence intervals of recombinant TS in the ELISA
Serum source
No. of patients Avg ELISA value
(95% confidence interval)Total Anti-TS negative Anti-TS positive
Healthy individuals 40 37 (0.925)a 3 0.51 (0.43–0.59)
Leishmaniasis patients 10 10 (1.0)a 0 0.52 (0.33–0.71)
Non-Chagas’ disease patientsb 50 47 (0.94)a 3 0.51 (0.44–0.58)
Chagas’ disease patients 151 3 148 (0.98)c 1.93 (1.82–2.04)
a The values in parentheses are percent specificity.
b Healthy individuals and patients with leishmaniasis.
c The value in parentheses is percent sensitivity.
VOL. 10, 2003 TRANS-SIALIDASE ELISA FOR CHAGAS’ DISEASE 827
specificity of 0.925. All serum samples from patients with vis-
ceral leishmaniasis presented values below the cutoff, with
mean values of 0.52. The specificity obtained when the results
for all serum samples from individuals without Chagas’ disease
are considered was estimated to be 0.94.
Evaluation of Chagas’ disease treatment. To investigate
whether the sera from benznidazole-treated patients with Cha-
gas’ disease displayed significant changes in reactivity to TS, we
tested sera from 124 patients with chronic Chagas’ disease
before and after treatment. Two samples were collected after
treatment at intervals of at least 1 year.
Three groups of individuals were identified on the basis of
the ELISA results. The first group, consisting of 60 patients,
had values greater than 1 (mean value, 1.71) before treatment,
and the first posttreatment samples showed a mean value of
0.91. The second sample (collected at least 1 year later)
showed a mean value of 0.72. In both cases, the posttreatment
samples presented values below the cutoff (Fig. 2A). These
results were confirmed by immunoblotting with each serum
sample. As shown in Fig. 2B, a serum sample collected before
treatment reacted well with TS, while a serum sample collected
from the same individual after treatment failed to do so. Sim-
ilar results were obtained when we tested sera from several
other patients, and no reaction was detected with sera from
leishmaniasis patients (data not shown). Most relevant was the
fact that this group of individuals had negative blood culture
test results and no clinical signs of infection.
The reactivities of the sera from the second group of patients
(n  46) are shown in Fig. 2C. The mean value for the serum
samples collected before treatment was 2.24, and the mean
values for samples collected 1 and 2 years after treatment
decreased to 1.49 and 1.39, respectively. Because these values
were above the mean for noninfected individuals, they were
considered positive. As expected, serum samples collected af-
ter treatment were still reactive with TS by immunoblotting,
but at lower intensities compared to those for the correspond-
ing samples collected before treatment (Fig. 2D). Four of the
46 individuals had positive blood culture test results.
Patients from the third group (n  18) were considered
resistant to treatment and presented clear signs of infection,
including positive blood cultures. The sera from these individ-
uals showed the same reactivities before and after treatment.
The mean values for samples collected before treatment and 1
and 2 years after treatment were 1.97, 1.86, and 1.97, respec-
tively (Fig. 2E). This result was confirmed by immunoblotting,
as shown in Fig. 2F.
Figure 3 shows the data plotted as the distribution of the
values for serum samples obtained from each group before and
after treatment. The linear regression clearly indicates that the
sera from the patients in the third group remained reactive to
TS.
DISCUSSION
The aim of the present study was to assess the possibility of
using recombinant TS for the diagnosis of Chagas’ disease and
the evaluation of treatment of Chagas’ disease patients. We
standardized a new ELISA to detect IgG antibodies against the
catalytic domain of TS by using a purified recombinant protein.
The population studied included adult patients with chronic
Chagas’ disease who had been infected more than three de-
cades earlier and who were hemoculture positive. As controls
we used apparently healthy individuals and patients with active
visceral leishmaniasis. The diagnostic value was high compared
to that of conventional serology for Chagas’ disease, with a
sensitivity of 0.98 and a specificity of 0.94. Individuals infected
with any Leishmania sp. always show low, albeit detectable,
titers for antibodies against T. cruzi antigens (18). In the
present assay, no cross-reaction was observed with sera from
patients with leishmaniasis. This observation is compatible
with the knowledge that members of the genus Leishmania do
no synthesize TS and confirms previous suggestions that an-
ti-TS antibodies can be used to distinguish T. cruzi-infected
individuals with other diseases, such as leishmaniasis (3).
More important, we have provided clear evidence that-an-
ti-TS antibody levels decrease upon benznidazole treatment, as
FIG. 2. Treatment follow-up. The reactivities of sera from chronic
Chagas’ disease patients with successful therapy (A), a decrease in
titers after treatment (C), and resistance to treatment (E) determined
before benznidazole treatment (E) and 1 year () and 2 years (‚)
after benznidazole treatment are shown. The values are the ratio of the
absorbance of each serum sample at 492 nm to the reaction cutoff.
Values greater than 1.0 were considered reactive. The horizontal lines
represent the arithmetic means. Immunoblots for serum samples from
the three groups of patients before treatment (Pre) and after treat-
ment (Post-T) are shown in panels B, D, and F, respectively.
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detected by ELISA with recombinant TS. We found a group of
patients who showed reactivities below the cutoff levels 2 years
after treatment and for whom no clinical symptoms or para-
sites were detectable by blood culture. This group was consid-
ered to have a distinct serological behavior after treatment. In
contrast, two groups of patients presented reactivities above
the cutoff after drug treatment. Posttherapy sera from one
group, formed by 37% of the patients, exhibited positive re-
sults, but the values were lower than those obtained before
treatment. This finding led us to assume that if treatment was
unable to abolish all the parasites, it at least reduced the
number of parasites in the circulation. Some of these patients
still showed evidence of active infection. A second group of
individuals corresponded to 14% of the patients and was con-
sidered to be resistant to treatment. Ten patients in this group
had positive blood culture test results and no clinical improve-
ment. They presented the same levels of anti-TS recognition
before and after treatment.
Previous studies have shown that anti-TS antibodies are
present in patients with active infection and that some of these
antibodies inhibit the activity of the enzyme (14, 24). On the
basis of this specific inhibition, the use of TS inhibition assays
has been proposed for the monitoring of treatment (3, 16). In
these studies the inhibitory antibodies seem to persist even
when infection disappears, as evaluated by clinical and other
immunological tests (15). In our case, the absence of a signif-
icant amount of antibodies distinguished the patients without
clinical symptoms of infection. One explanation for this appar-
ent contradiction is the fact that our method detected a dif-
ferent population of antibodies against TS, which may repre-
sent the majority of antibodies against the enzyme. These
antibodies could possibly bind to the enzyme portions not
involved in substrate binding. In addition, we used a solid-
phase assay in which most of the accessible epitopes could be
distinct from the substrate binding site. It would be interesting
to compare the epitopes recognized by the different types of
antibodies.
It has been accepted that the titers of protective IgG anti-
bodies against trypomastigote antigens decrease following che-
motherapy, when most of the parasites are eliminated (1, 7,
13). These antibodies were shown to react to parasite surface
components (19), inducing complement-mediated lysis of try-
pomastigotes (11). Some are directed at proteins that induce
complement resistance to the parasites (21); but some other
trypomastigote antigens, such as mucins (2), proteins (7), and
excreted antigens (29), have also been shown to detect a de-
crease in the levels of protective antibodies. In contrast, the
levels of antibodies to epimastigote antigens are not dramati-
cally changed after treatment. Such dissociation has been used
as a criterion of cure in successfully treated patients (11).
In summary, the present data show that the catalytic domain
of TS can also be used for the diagnosis and monitoring of
Chagas’ disease treatment, providing a simple methodology for
monitoring the results of chemotherapy for Chagas’ disease
patients. After drug treatment the sera of some patients
showed reduced reactivities, while the sera of other patients
had more discrete changes in reactivity. Compared to other
methods that use TS, the present one is simpler and does not
depend on the measurement of TS activity, especially when
several serum samples with serial dilutions should be used. The
effective cure of the infection, however, requires negative re-
sults by clinical, serological, and parasitological tests after a
long period of monitoring. Long-term clinical monitoring of
the same patients is being conducted by one of us, and pre-
liminary data suggest that benznidazole treatment is effective
for most patients in the chronic phase of Chagas’ disease.
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